OneSource partners have secured Canada approval, generic semaglutide injection, a major step that could make diabetes treatment more affordable while boosting competition in the rapidly growing GLP-1 drug market.
OneSource Specialty Pharma, along with its partners including Orbicular and a Canadian front-end collaborator, received approval from Health Canada to launch a generic version of semaglutide. This drug is widely known as the key ingredient in popular diabetes treatments like Ozempic. The approval places the company among the early entrants in Canada’s emerging pharmaceutical market.
The timing of this development is significant. Demand for semaglutide-based medicines has been rising sharply across the world due to their strong results in controlling type 2 diabetes and aiding weight management. As patents for branded versions begin to expire in certain regions, pharmaceutical companies are moving quickly to introduce cost-effective generic drugs.
Canada has become an important market for such launches because of its supportive regulatory environment and strong demand for affordable healthcare options. With this approval, OneSource and its partners are expected to capture early market share and strengthen their presence in regulated markets.
Also Read: Takeda Immune Drug Shows Strong Results in Late Study
OneSource will play a key role in manufacturing the drug through its advanced facility in Bengaluru, which meets international regulatory standards. This also highlights India’s growing role in global pharmaceutical supply chain and production of complex medicines.
Industry experts believe that the entry of more generic versions could significantly reduce treatment costs. In many cases, generic drugs in Canada are priced much lower than branded medicines, improving healthcare affordability for a wider population.
For OneSource, this approval also signals positive momentum after facing earlier regulatory delays. It strengthens the company’s position in the global pharmaceutical space and opens up new growth opportunities.
As more companies enter the segment, the semaglutide market is expected to become more competitive, ultimately benefiting patients through better access and lower prices.
.jpg)
.jpg)
